Latanoprost + Timolol

Generic Medicine Info
Indications and Dosage
Ocular hypertension, Open-angle glaucoma
Adult: Available preparation:
Latanoprost 50 mcg and timolol 5 mg per mL of eye drop solution

In patients who do not adequately respond to topical β-blockers or prostaglandin analogues: Instil 1 drop into the affected eye(s) once daily.
Latanoprost: May form precipitate with thiomersal-containing eye drops.
Reactive airway disease (e.g. existing or history of bronchial asthma, severe COPD); sinus bradycardia, sick sinus syndrome, sino-atrial block, 2nd- or 3rd-degree atrioventricular block (not controlled with a pacemaker), overt cardiac failure, cardiogenic shock; active herpes simplex keratitis or history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.
Special Precautions
Patients with history of atopy or severe anaphylaxis to allergens, 1st-degree heart block, heart failure, orthostatic hypotension, severe peripheral circulatory disturbance or disorders (e.g. severe forms of Raynaud’s syndrome), mild or moderate COPD, diabetes (especially labile diabetes), hyperthyroidism, corneal diseases, other types of glaucoma (e.g. inflammatory, neovascular or chronic angle-closure glaucoma, open-angle glaucoma of pseudophakic patients, pigmentary glaucoma), closed-angle glaucoma (as monotherapy), history of herpetic keratitis, active intraocular inflammation; aphakic patients, pseudophakic patients with torn posterior lens capsule, risk factors for macular oedema; myasthenia gravis. Patients undergoing surgery.
Adverse Reactions
Significant: Choroidal detachment (post-filtration procedures), increased iris pigmentation, eyelid skin and eyelash changes (increased length, darkening and thickening of the eyelashes), anaphylactic reactions, bacterial keratitis, macular oedema (e.g. cystoid macular oedema).
Eye disorders: Eye pain or irritation (e.g. stinging, burning, itching, foreign body sensation), blepharitis, blurred vision, corneal disorder, conjunctivitis, eye hyperaemia.
Nervous system disorders: Dizziness, headache.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Cardiac failure; bronchospasm (in patients with asthma).
Patient Counseling Information
Remove contact lenses before administration and reinsert after 15 minutes. This drug may cause transient blurring of vision, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor intraocular pressure, changes in iris colour and eyelash; systemic effects of β blockade; signs and symptoms of heart failure.
Symptoms: Latanoprost: Ocular irritation and conjunctival hyperaemia.
Timolol (systemic): Bradycardia, hypotension, bronchospasm and cardiac arrest.
Management: Symptomatic and supportive treatment.
Drug Interactions
May have potentiated effects on intraocular pressure or systemic β-blockade with oral or other topical β-adrenergic blockers.
Latanoprost: Paradoxical increase in intraocular pressure with another prostaglandin analogues.
Timolol: May have additive effects resulting in hypotension and/or notable bradycardia with oral Ca channel blockers, guanethidine, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Potentiated systemic β blockade (e.g. decreased heart rate, depression) with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine). May result in mydriasis with epinephrine. May potentiate the hypertensive reaction to sudden withdrawal of clonidine. May increase the hypoglycaemic effect of anti-diabetic agents.
Description: Latanoprost, a prostaglandin F analogue, is a selective prostanoid FP receptor agonist which reduces IOP by primarily increasing the uveoscleral outflow of the aqueous humour.
Timolol, a non-selective adrenergic receptor antagonist, reduces IOP by decreasing the production of aqueous humour in the ciliary epithelium.
Onset: Within 1 hour.
Latanoprost: Intraocular pressure reduction: 3-4 hours.
Timolol: Intraocular pressure reduction: 30 minutes.
Duration: Up to 24 hours.
Timolol: 24 hours.
Absorption: Latanoprost: Well-absorbed through the cornea. Bioavailability: 45% (acid of latanoprost). Time to reach maximum concentration in the aqueous humour: 2 hours.
Timolol: Partly absorbed systemically. Time to reach maximum concentration in the aqueous humour: Approx 1 hour. Time to peak plasma concentration: 10-20 minutes.
Distribution: Latanoprost: Volume of distribution: Approx 0.16 L/kg (acid of latanoprost). Plasma protein binding: 87%.
Timolol: Enters breast milk.
Metabolism: Latanoprost: Primarily metabolised in the liver via fatty acid beta-oxidation.
Timolol: Extensively metabolised in the liver.
Excretion: Latanoprost: Mainly via urine (as metabolites). Elimination half-life: 17 minutes (acid of latanoprost).
Timolol: Via urine (as metabolites with some unchanged drug). Elimination half-life: Approx 6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Latanoprost, CID=5311221, (accessed on Jan. 22, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Timolol, CID=33624, (accessed on Jan. 21, 2020)

Store between 2-8°C. Opened bottle: Store below 25°C; use within 4 weeks. Protect from light.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
Anon. Latanoprost and Timolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/12/2020.

Anon. Latanoprost. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/12/2020.

Anon. Timolol (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/12/2020.

Buckingham R (ed). Latanoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/12/2020.

Buckingham R (ed). Timolol Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/12/2020.

Joint Formulary Committee. Latanoprost with Timolol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 17/12/2020.

Xalacom 50 mcg/mL + 5 mg/mL, Eye Drops, Solution (Pfizer Ltd). MHRA. Accessed 17/12/2020.

Xalacom Eye Drops, Solution (Pfizer Manufacturing Belgium NV). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 17/12/2020.

Disclaimer: This information is independently developed by MIMS based on Latanoprost + Timolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Latocom
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in